CRIS OUT-BACK PROGRAMME 2021 Researcher: Diego Benito Institution: Home: Universidad de Navarra, SPAIN – HOST: Massachusetts General Hospital Cancer Center (USA) Ovarian cancer has a 5-year survival rate of just 40%, due to its late diagnosis and aggressiveness. Although immunotherapy is showing good results in other types of tumours, in ovarian cancer the results are

CRIS OUT-BACK PROGRAMME 2021 Researcher: Rebeca González Institution:Home: INSTITUTO DE NEUROCIENCIAS CSIC-UMH, SPAIN – Host: Centre Méditerranéen de médecine moléculaire, France Melanoma is a very aggressive type of skin cancer experienced by more than 6000 people a year in Spain. It is the most aggressive skin tumour and most often metastasises. If metastasis occurs, in

CRIS POST-DOC TALENT PROGRAMME 2021 Researcher: Dra. Blanca Majem Cavaller Institution:Institut de Recerca Biomèdica (IRB), Barcelona Introduction: Tumour metastases represent the greatest challenge in cancer research. More than 90% of tumour deaths occur because of the consequences of metastases, yet a great deal is still unknown about the mechanisms that produce metastases and how to

CRIS POST-DOC TALENT PROGRAMME 2021 Researcher: Dra. Ceres Fernández Rozadilla Institution:Instituto de Investigación Sanitaria de Santiago de Compostela Colon or bowel cancer is the most diagnosed form of cancer in Spain (43,500 cases per year) and the second highest cause of death from cancer (16,500 people a year) after lung cancer. It is a complex

CRIS EXCELLENCE PROGRAMME 2021 Researcher: Dr. Arkaitz Carracedo Institution:CIC Biogune, Bilbao Introduction: Prostate cancer is the most prevalent form of cancer in men, causing more than 80,000 deaths a year in the European Union. Although most respond to treatments, these tumours have certain characteristics that make them a real medical challenge.  On the one hand,

CRIS EXCELLENCE PROGRAMME 2021 Researcher: Dr. Aleix Prat Institution: Hospital Clínic, Barcelona Introduction: Breast cancer remains one of the biggest challenges in cancer research. 1 out of 8 women will develop breast cancer at some time in their lives.  Breast tumours are generally classified according to whether or not the tumour cells possess certain molecules

CRIS CLINICAL TALENT PROGRAMME 2021 Researcher: Dra. Nuria Romero Laorden Institution: Hospital de La Princesa, Madrid Introduction: We tend to see prostate cancer as relatively benign and curable, but approximately 10% of patients have metastases and do not respond to usual treatments. These patients have a life expectancy of less than 3 years, and account

CRIS CLINICAL TALENT PROGRAMME 2021 Researcher: Dra. Ana Jiménez Ubieto Institution: Hospital Universitario 12 de octubre, Madrid Introduction: Follicular lymphoma is one of the most common types of blood cancer. Although it tends to be relatively non-aggressive, it still currently has no cure. In addition, a significant number of patients (between 15% and 20%) relapse

Project: Resistance to treatments for Multiple Myeloma  Institution: Institute of Cancer Research, London (UK)  Researcher: Dr. Charlotte Pawlyn  What is this project about? This research project aims to define a profile of multiple myeloma patients likely to develop resistance to myeloma treatments, study reasons why such resistance occurs and develop useful therapeutic strategies to overcome this.  What is multiple myeloma?  Multiple myeloma is a cancer that begins in the bone marrow in a type

Principal Investigator: Dr Astero Klampatsa Centre:Institute of Cancer Research, London (United Kingdom) Background:   Mesothelioma is a type of thoracic tumour that occurs in the mesothelium. This is the cell layer that covers several of the organs contained in the thoracic cavity. We now know that one of its main causes is exposure to asbestos (also called amianthus). Although asbestos now appears to be a thing of the past, a large number of people